DYDROGYN
UNION PHARMACEUTIQUE CONSTANTINOISE
Identification
- Active ingredient (INN)
- DYDROGESTERONE MICRONISEE
- Internal code
- 09 N 060
- Country of Origin
- Algeria
- Pharmaceutical form
- Film-coated Tablet
- Prescription List
- Highly Regulated (List I)
- Packaging
- b/10

DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Description
A synthetic progestational hormone with no androgenic or estrogenic properties.
Unlike many other progestational compounds, dydrogesterone produces no increase in temperature and does not inhibit ovulation.
Indications
Used to treat irregular duration of cycles and irregular occurrence and duration of periods caused by progesterone deficiency.
Also used to prevent natural abortion in patients who have a history of habitual abortions.
Pharmacodynamics
Dydrogesterone is an
Oral active progestogen which acts directly on the uterus, producing a complete secretory endometrium in an estrogen-primed uterus.
At therapeutic levels, dydrogesterone has no contraceptive effect as it does not inhibit or interfere with ovulation or the corpus luteum.
Furthermore, dydrogesterone is non-androgenic, non-estrogenic, non-corticoid, non-anabolic and is not excreted as pregnanediol.
Dydrogesterone helps to regulate the healthy growth and normal shedding of the uterus lining.
Therefore, it may be useful in the treatment of menstrual disorders such as absent, irregular or painful menstrual periods, infertility, premenstrual syndrome and endometriosis.
Absorption
Rapidly absorbed in the gastrointestinal tract with a bioavailability of 28%.
Metabolism
is complete to a 20-dihydrodydrogesterone (DHD) metabolite.
Hover over products below to view reaction partners Dydrogesterone 20-dihydrodydrogesterone.
Adverse Effects
Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.
Toxicity
No serious or unexpected toxicity has been observed with dydrogesterone.
In acute toxicity studies, the LD50 doses in rats exceeded 4,640 mg/kg for the oral route.